Compare McCormick & Company, Incorporated (MKC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Repligen Corporation Common Stock — how do they compare? McCormick & Company, Incorporated trades at $45.03 (market cap $12.02B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: McCormick & Company, Incorporated and Repligen Corporation Common Stock are close in size by market cap, and McCormick & Company, Incorporated pays a 4.3% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 68 Days and Repligen Corporation Common Stock for 0 Days on average.
| MKC | RGEN | |
|---|---|---|
Market Cap | $12.02B | $11.14B |
Volume | 3,822,006 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $194.57 |
52-Week Low | $44.14 | $102.87 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $16.71B | $11.02B |
Dividend Yield | 4.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $44.80, down 1.71% on the day, with a bearish technical signal from moving averages. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Valuation ratios appear attractive with a P/E of 8.07 and net income margin of 19.39%. Recent news highlights the acquisition of McCormick de Mexico and a reaffirmed 2026 outlook.
The stock offers value with solid profitability and dividend growth, but faces near-term technical headwinds and mixed analyst sentiment. Upside exists toward the $53.50 consensus target, though execution risks and market volatility require monitoring. The current price near support at $44 suggests a potential entry point for long-term investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
